Novavax

TODAY: John Jacobs, President and Chief Executive Officer, Jim Kelly, Executive Vice President, Chief Financial Officer and Treasurer, and Ruxandra Draghia Akli, MD, PhD, Executive Vice President and Head of Research and Development, will be representing Novavax in a Fireside Chat at the TD Cowen 45th Annual Health Care Conference in Boston, MA. Event details and webcast information: https://lnkd.in/eUF7Htau

At Novavax, we don’t just focus on what we do, we are driven by why we do it. Today, we’re proud to unveil our new Mission and Vision Statements based on our new corporate growth strategy —the compass that steers each decision we make, every innovation we advance, and every collaboration we undertake. Learn more: https://novav.ax/4bfAYX1 #MissionStatement #VisionStatement

Today we shared our financial results and earnings from the fourth quarter and full year 2024. Read the full report: https://novav.ax/43y9pXd   #Earnings #FinancialResults 

Novavax's conference call to discuss fourth quarter and full year 2024 financial results and operational highlights is today at 8:30 a.m. ET. Register and tune-in at: https://novav.ax/41sFQ7Q

We are actively advancing our pipeline - both late- and early-stage programs - using a rigorous set of principles to guide our selection process and focus on high-value assets in areas with unmet medical need, compelling scientific rationale and strong commercial opportunity. To learn more, click here: https://novav.ax/40Dgm5Z

We are honored to share that the Novavax and Sanofi partnership was selected as the "Top Alliance of 2024" in Citeline's 17th Annual In Vivo Deals of the Year awards. Thank you to the teams that contributed to this work and continue to focus on making Novavax a partner of choice. Learn more: https://novav.ax/41gVfqm

As part of our R&D strategy, we are actively advancing our early-stage pipeline with a focus on high-value assets in areas with unmet medical need, compelling scientific rationale and strong commercial opportunity to support long-term growth. To learn more, click here: https://novav.ax/43aibuh

Novavax's conference call to discuss fourth quarter and full year 2024 financial results and operational highlights is February 27 at 8:30 a.m. ET. More information: https://novav.ax/4ipVTcn

We believe Matrix-M ™ can benefit other companies’ vaccines by improving the activity of existing vaccines, while maintaining excellent tolerability. To learn more, click here: https://novav.ax/3WA5hkP

Novavax’s technology platform combined with our deep vaccine expertise is the fuel for future innovation and partnerships. The unique platform features two key elements: recombinant protein-based nanoparticles and Matrix-M™ adjuvant. To learn more, click here: https://novav.ax/40RYhT9